c
2
12
18
28
12
12
1a
14
e
12
16
a
a
2
2
a
20
32
1a
2a
19
Faculty
61 16
19
1
49
2
2
1a
32
34
1b
1d
18
37
45
1d
2 29
1d
25
David John Irwin, MD, MTR
78
45
Associate Professor of Neurology
7
60
Department: Neurology
4
1
23
1f
Graduate Group Affiliations
8
b
-
64
- Neuroscience e
1d
46
Contact information
58
4
3
3
1d
58
Hospital of the University of Pennsylvania
1f Department of Neurology
40 3400 Spruce Street, 3 W Gates
Philadelphia, Pa 19104
26
1f Department of Neurology
40 3400 Spruce Street, 3 W Gates
Philadelphia, Pa 19104
2e
Office: 215-573-6417
32 Fax: 215-349-5579
32 Lab: 215-573-1912
18
f
32 Fax: 215-349-5579
32 Lab: 215-573-1912
18
18
Publications
23 a
3
2
4
b
1f
23 a
13
Education:
21 7 BA c
28 Drew University, 2001.
21 7 MD c
3e Drexel University College of Medicine, 2006.
21 8 MTR c
4f University of Pennsylvania Perelman School of Medicine, 2015.
c
3
27
21 7 BA c
28 Drew University, 2001.
21 7 MD c
3e Drexel University College of Medicine, 2006.
21 8 MTR c
4f University of Pennsylvania Perelman School of Medicine, 2015.
c
Links
b5 Search PubMed for articles
82 Google Scholar Profile
6f Irwin Lab Website
71 Research Gate Profile
b6 PubMed Bibliography
c
5
3
3
92
Permanent linkb5 Search PubMed for articles
82 Google Scholar Profile
6f Irwin Lab Website
71 Research Gate Profile
b6 PubMed Bibliography
c
2 29
21
1e
1d
24
5e
e 7 1d 1f
27
Description of Research Expertise
431 The overall mission of my translational research program is to improve the diagnosis and treatment for young-onset and atypical neurodegenerative dementias. A major limitation for therapeutic trials in these disorders is that the gold-standard for diagnosis is neuropathological examination at autopsy. To address this problem, my lab (Penn Digital Neuropathology Lab) develops novel open-source digital image analysis tools to study gold-standard histopathology in an objective and reproducible manner with rigorous validation. My lab utilizes both innovative “wet-lab” human brain histology techniques and novel “dry-lab” digital image analysis methods and bioinformatics to integrate fine-grained measures of postmortem neuropathology with antemortem clincial data. My goal is to identify diagnostic and prognostic markers of disease progression that can serve as endpoints in treatment trials. The approach of my lab represents the blending of my training in two separate but complementary specialties of cognitive neurology and neuropathology.e 7 1d 1f
4d
22
22
7
10
a
a
2
2
19
18
10
22
10
11
c
5b © The Trustees of the University of Pennsylvania | Site best viewed a in a supported browser. | Site Design: 57 PMACS Web Team. 3 22
10